{"filing":{"accession_number":"0001193125-26-428943","cik":"0001774857","ticker":"AARD","company_name":"Aardvark Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-22","primary_document":"ck0001774857-20261022.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526428943/ck0001774857-20261022.htm"},"events":[{"id":37259,"run_id":34349,"accession_number":"0001193125-26-428943","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The FDA's lifting of the clinical hold on ARD-101 is a material regulatory milestone that permits resumption of clinical development for Aardvark's lead program in Prader-Willi Syndrome. This is a significant operational and regulatory event—not a specific named type like earnings, M\u0026A, or litigation—that directly affects the company's ability to advance its pipeline and would materially impact investor assessment of the registrant's prospects.","company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41916,"accession_number":"0001193125-26-428943","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA's lifting of the clinical hold on ARD-101 is a material regulatory milestone that permits resumption of clinical development for Aardvark's lead program in Prader-Willi Syndrome. This is a significant operational and regulatory event—not a specific named type like earnings, M\u0026A, or litigation—that directly affects the company's ability to advance its pipeline and would materially impact investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:19:18.757608+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41916,"accession_number":"0001193125-26-428943","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The FDA's lifting of the clinical hold on ARD-101 is a material regulatory milestone that permits resumption of clinical development for Aardvark's lead program in Prader-Willi Syndrome. This is a significant operational and regulatory event—not a specific named type like earnings, M\u0026A, or litigation—that directly affects the company's ability to advance its pipeline and would materially impact investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T20:19:18.757608+00:00","company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","filing_date":"2026-10-22"}]}